News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Corcept Therapeutics Inc. (CORT) and Xceleron Inc Sign Agreement for Microdosing Study Using Accelerator Mass Spectrometry


7/25/2007 8:42:53 AM

MENLO PARK, CA--(MARKET WIRE)--Jul 25, 2007 -- Corcept Therapeutics (NasdaqCM:CORT - News) and Xceleron today announced an agreement for a human microdosing study of one of Corcept's new chemical entities, a selective GR-II antagonist, utilizing Xceleron's Accelerator Mass Spectrometry (AMS) technology.

Read at press release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES